Difference between revisions of "Strontium-89 (Metastron)"
Jump to navigation
Jump to search
(Created page with "==General information== Radioactive strontium ==Diseases for which it was used== *Prostate cancer ==History of changes in FDA indication== *6/18/1993: Initial approval...") |
m |
||
| (4 intermediate revisions by the same user not shown) | |||
| Line 6: | Line 6: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | *1993-06-18: Initial approval for the relief of bone pain in patients with painful skeletal metastases. |
| + | ==History of changes in PMDA indication== | ||
| + | *2007-07-31: Initial approval for pain relief in bone scintigraphy-positive metastatic lesions in patients with solid cancers. | ||
| + | ==Also known as== | ||
| + | *'''Brand name:''' Metastron | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Radiotherapy medications]] | [[Category:Radiotherapy medications]] | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
| − | + | [[Category:Prostate cancer medications]] | |
[[Category:FDA approved in 1993]] | [[Category:FDA approved in 1993]] | ||
| + | [[Category:PMDA approved in 2007]] | ||
| + | [[Category:Stub]] | ||
Latest revision as of 00:40, 11 June 2023
General information
Radioactive strontium
Diseases for which it was used
History of changes in FDA indication
- 1993-06-18: Initial approval for the relief of bone pain in patients with painful skeletal metastases.
History of changes in PMDA indication
- 2007-07-31: Initial approval for pain relief in bone scintigraphy-positive metastatic lesions in patients with solid cancers.
Also known as
- Brand name: Metastron